Drug General Information
Drug ID	D0Q5KZ
Former ID	DNCL002566
Drug Name	SGI110
Indication	Acute myeloid leukemia; Myelodysplastic syndrome [ICD9: 205, 238.7; ICD10:C92.0, D46]		Phase 3	[525074]
Company	Astex Pharmaceuticals
Structure		Download 2D MOL
Target and Pathway
Target(s)	DNMT1	Target Info	Modulator	[533185]
KEGG Pathway	Cysteine and methionine metabolism
	Metabolic pathways
	MicroRNAs in cancer
Pathway Interaction Database	Regulation of retinoblastoma protein
PathWhiz Pathway	Methionine Metabolism
Reactome	PRC2 methylates histones and DNA
	NoRC negatively regulates rRNA expression
	DNA methylation
WikiPathways	Trans-sulfuration and one carbon metabolism
	Retinoblastoma (RB) in Cancer
	One Carbon Metabolism
	Trans-sulfuration pathway
References
Ref 525074	ClinicalTrials.gov (NCT02348489) SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction. U.S. National Institutes of Health.
Ref 533185	Immunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts. Epigenetics. 2015;10(3):237-46.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.